Aerobic Exercise Training (AET) for Usual Interstitial Pneumonia

Phase-Based Progress Estimates
INOVA Fairfax Hospital, Falls Church, VA
Usual Interstitial Pneumonia+7 More
Aerobic Exercise Training (AET) - Other
All Sexes
Eligible conditions

Study Summary

The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease

See full description

Eligible Conditions

  • Usual Interstitial Pneumonia
  • Desquamative Interstitial Pneumonia
  • Interstitial Lung Diseases (ILD)
  • Interstitial Pneumonitis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

This trial is evaluating whether Aerobic Exercise Training (AET) will improve 1 primary outcome and 2 secondary outcomes in patients with Usual Interstitial Pneumonia. Measurement will happen over the course of Baseline, after 10 weeks, after 20 weeks (for crossover group).

Week 20
Patient-reported outcomes
Treadmill cardiorespiratory exercise test (CPET)
Week 20
6MWT distance

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

1 of 2
1 of 2
Active Control
Experimental Treatment

This trial requires 60 total participants across 2 different treatment groups

This trial involves 2 different treatments. Aerobic Exercise Training (AET) is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

AET will consist of a 10-week regimen of supervised treadmill walking three times a week. The duration of the exercise sessions will progress from 30 minutes to 45 minutes per session over the 10 weeks as tolerated. The intensity of the exercise will be between 70 and 80% of the patient's heart rate reserve.
No AETcontrol will not engage in AET.

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, after 10 weeks, after 20 weeks (for crossover group)
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly baseline, after 10 weeks, after 20 weeks (for crossover group) for reporting.

Closest Location

INOVA Fairfax Hospital - Falls Church, VA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 5 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
A diagnosis of interstitial lung disease, including idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonitis (NSIP), sarcoidosis, or other form of chronic lung fibrosis based on clinical context via clinic note from a pulmonologist.
Individuals with ILD referred for pulmonary rehabilitation who are 21-80 years of age and live in the Washington metropolitan area.
No episodes of fainting or significant chest pain for at least one month.
No prior pulmonary rehabilitation received within the last 6 months and not currently in a maintenance program.
Physically inactive (no participation in a structured exercise program as defined as more than 30 minutes of exercise 3 or more days a week within the last 6 months).

Patient Q&A Section

What is lung diseases?

"Lung diseases are a diverse group of diseases that involve diseases of the respiratory system including those that cause obstruction of airways and are classified principally on whether the origin of the disease lies with the lungs or elsewhere. Lung diseases can be classified by the location and specific types of lesions that they are most likely to produce. Lung diseases can be classified according to whether their cause lies with infectious agents, autoimmune disorders, neoplastic processes or adverse effects of therapeutic and environmental factors. The following subsections describe a sample of the lung diseases classified as part of these categories.\n\nLung diseases can be either "localised" or "generalised"." - Anonymous Online Contributor

Unverified Answer

What are common treatments for lung diseases?

"The common treatments for lung diseases include avoidance of smoking, use of bronchodilators and anti-histamines. If the cause of the condition is confirmed, treatment may be tailored according to the cause. There is limited evidence of benefit for alternative treatments." - Anonymous Online Contributor

Unverified Answer

Can lung diseases be cured?

"Lung disease can be strongly reduced with appropriate treatment, but not completely cured (symptom-free) in most cases. However, due to better anti-inflammatory treatment options and new treatment approaches, the risks of lung disease complications are getting diminished." - Anonymous Online Contributor

Unverified Answer

What causes lung diseases?

"There exists an urgent need to reduce the risk of chronic obstructive pulmonary diseases, in particular COPD, by identifying causes and risk factors and implementing preventive and disease management measures." - Anonymous Online Contributor

Unverified Answer

What are the signs of lung diseases?

"Lung diseases are associated with chest pain, shortness of breath, dizziness, and cough. A chest CT scan may be useful to help determine the disease." - Anonymous Online Contributor

Unverified Answer

How many people get lung diseases a year in the United States?

"Of the 33 most common lung diseases in the United States, 14 causes (42%) are associated with significant disease burden. Chronic obstructive pulmonary disease, bronchitis, acute bronchitis, pneumonia, and asthma made up about half of these. Lung diseases are a leading cause of hospitalizations in US; this burden is even greater in the frail elderly and those with other co-morbidities." - Anonymous Online Contributor

Unverified Answer

Does lung diseases run in families?

"The current study provides evidence of a genetic aetiology associated with pulmonary complications in a relatively homogeneous population of non-responders. We identified a distinct pattern of family aggregation and suggestive linkage." - Anonymous Online Contributor

Unverified Answer

Does aerobic exercise training (aet) improve quality of life for those with lung diseases?

"aet improves physical functioning as well as quality of life. The improvement of quality of life may be useful to allow patients to achieve a better level of activity, thus increasing their fitness and therefore preventing physical complications, such as cardiovascular disease, pulmonary disorders (symptom relief), and osteoporosis." - Anonymous Online Contributor

Unverified Answer

Who should consider clinical trials for lung diseases?

"The majority of doctors and patients would not consider a lung disease to be a target for clinical trials even though evidence from clinical trials suggests that some conditions have a positive outcome if treated with medication. However, only a small minority of patients would consider themselves to be research participants in any form of trial of lung diseases." - Anonymous Online Contributor

Unverified Answer

What is the primary cause of lung diseases?

"Lung diseases are the leading cause of morbidity and mortality in the United States. A multifactorial perspective is important to identify their causal basis so that we can develop lung disease-specific preventive, diagnostic and treatment strategies. The epidemiology of lung diseases is complex and a combination of shared and unique determinants is expected to explain disease patterns." - Anonymous Online Contributor

Unverified Answer

What are the common side effects of aerobic exercise training (aet)?

"Despite a wide range of responses to aet, most studies have found improvements in cardio-respiratory fitness in COPD patients when training is combined with medication. Exercise testing is necessary to assess exercise capacity so the optimum exercise training intensity for patients with COPD is yet to be determined." - Anonymous Online Contributor

Unverified Answer

Is aerobic exercise training (aet) safe for people?

"Data from a recent study do not support the opinion that aet is a risk factor for the development of an increased risk of any event other than infection, or that it increases the risk of cancer or cardiac events. This conclusion is based on a review of 1,088 participants in 14 clinical trials which included a total of over 23,600 participants (average 5-year follow-up)." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Usual Interstitial Pneumonia by sharing your contact details with the study coordinator.